Pitt Shield

THE MODULATION OF THE BLOOD-BRAIN BARRIER BY FOCUSED ULTRASOUND STIMULATES OLIGODENDROGENESIS.

Authors: Noseworthy K, Silburt J, Hynynen K, Aubert I

The current study aims to fill a gap in knowledge on the effects of focused ultrasound (FUS)-mediated blood-brain-barrier (BBB) modulation on the proliferation and development of oligodendrocyte progenitor cells (OPCs). Researchers established that FUS combined with intravenous microbubbles can modulate the BBB in a controlled, reversible, localized, and non-invasive manner to facilitate the delivery of intravenous therapeutics to the brain. Over a decade ago, we discovered that, even without intravenous therapeutics, FUS-BBB modulation stimulates elements of brain repair, including hippocampal neurogenesis. In adult mice, FUS-BBB modulation was targeted unilaterally to the hippocampus and proliferation of OPCs was quantified at 1, 4, 7, and 10 days post-FUS. Mature oligodendrocytes were quantified at 30 days post-FUS. OPC proliferation was assessed at 7 days post-FUS, and mature oligodendrocytes at 30 days. The proliferation of hippocampal OPCs was increased by 6.8-fold and 2.3-fold between 1 and 4 days post-sonication, respectively, resulting in a 5.3-fold increase in mature oligodendrocytes one month later. To test the robustness of oligodendrogenesis following FUS-BBB modulation, the striatum was targeted as a second brain region with an independent experimental design. In line with hippocampal results, striatal FUS-BBB modulation promoted the generation of OPCs by 3.9-fold during the first week, leading to a 5.2-fold increase in oligodendrogenesis 30 days post-treatment. We conclude that FUS-BBB modulation in the hippocampus and striatum promotes oligodendrogenesis by stimulating the proliferation of OPCs and being permissive to their maturation.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To determine whether transient focused ultrasound–mediated blood–brain barrier (FUS-BBB) modulation promotes proliferation of oligodendrocyte progenitor cells and their maturation into oligodendrocytes in the adult mouse hippocampus and striatum.
Animal model / Human subject Mouse (Mus musculus), C57BL/6J, 2.5-3.5 months old, male
Disease model Healthy
MRI or image guidance method MRI-guided targeting (T2-weighted MRI mapping to select focal spots with MRI-guided FUS system and T1-weighted Gadovist contrast to confirm BBB opening)
Targeted brain region(s) Striatum
Cargo name and characteristics Bromodeoxyuridine (BrdU) — thymidine analog nucleoside (proliferation marker), administered i.p. (50 mg/kg, twice daily for 4 days); 5-ethynyl-2'-deoxyuridine (EdU) — thymidine analog nucleoside (proliferation marker), administered i.p. (50 mg/kg, once daily for 7 days); Gadovist (gadobutrol) — gadolinium-based MRI contrast agent (small molecule, 0.2 ml/kg i.v.)
Route of administration Intraperitoneal (i.p.) for BrdU and EdU; Intravenous (tail-vein) for Gadovist (contrast agent)

Outcomes and Safety

Summary of Outcomes Focused ultrasound blood–brain barrier (FUS-BBB) modulation with intravenous microbubbles, delivered as a single unilateral sonication to the hippocampus or striatum, rapidly increased OPC proliferation (hippocampus: 6.8-fold at 1 day and 2.3-fold at 4 days; striatum: 3.9-fold at 7 days) and produced robust increases in mature oligodendrocytes by 30 days (hippocampus ~5.3-fold; striatum ~5.2-fold). The study did not compare multiple FUS parameter sets — these effects were observed using a standard single-sonication FUS-BBB modulation paradigm with IV microbubbles targeted to hippocampus or striatum.
Duration of biological effect 4 days
Safety-related matter FUS-BBB modulation transiently activates astrocytes and microglia and induces an acute, short-term inflammatory response (microglial reactivity observed as early as 1 hour and up to 7 days, suggested to resolve after ~2 weeks). The paper does not report any adverse effects or safety issues observed in these experiments.

Brain Region

Ultrasound Parameters

Ultrasound instrument In-house developed prototype of LP100 (FUS Instrument Inc., Toronto, ON, Canada); spherically focused transducer (1.68 MHz for hippocampal targeting, 1.78 MHz for striatal targeting), 75 mm diameter, 60 mm radius of curvature
FUS Frequency 1.68 MHz, 1.78 MHz
FUS Mode pulsed
Pulse duration 10 ms
Duration of a single FUS session 120 seconds
Focal Characteristics Focal depth: 1 mm; Focal length: 60 mm (radius of curvature); Aperture size: 75 mm (diameter)
Treatment frequency Single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search